Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature (3)
Nature Communications (1)
Nature Genetics (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (4)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Drug discovery
Immunology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–5 of 5 results

Advanced filters: Author: Roel Funke Clear advanced filters

Why animals have different muscle fibre types

Lawrence C. Rome
Roel P. Funke
Marvin Freadman
Research27 Oct 1988
Nature

Volume: 335, P: 824-827
Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy

Stephan Rust
Michael Walter
Gerd Assmann
Research01 Sept 1998
Nature Genetics

Volume: 20, P: 96-98
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combination with bevacizumab in ten patients with metastatic renal cell carcinoma.

Jeffrey J. Wallin
Johanna C. Bendell
David F. McDermott
ResearchOpen Access30 Aug 2016
Nature Communications

Volume: 7, P: 1-8
Non-viral precision T cell receptor replacement for personalized cell therapy

A first-in-human phase I clinical trial demonstrates the feasibility and safety of non-viral precision genome-engineering of a personalized adoptive cell transfer anticancer therapeutic.

Susan P. Foy
Kyle Jacoby
Stefanie J. Mandl
ResearchOpen Access10 Nov 2022
Nature

Volume: 615, P: 687-696
Initial sequencing and analysis of the human genome

Eric S. Lander
Lauren M. Linton
Michael J. Morgan
articles01 Feb 2001
Nature

Volume: 409, P: 860-921

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com footer links

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2026 Springer Nature Limited